Entero Therapeutics (ENTO) Competitors $0.42 -0.02 (-4.45%) Closing price 08/1/2025 03:48 PM EasternExtended Trading$0.44 +0.01 (+3.47%) As of 08/1/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. NKGN, AEON, KPRX, TRAW, MBIO, ADXN, APM, DWTX, BMRA, and GNPXShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include NKGen Biotech (NKGN), AEON Biopharma (AEON), Kiora Pharmaceuticals (KPRX), Traws Pharma (TRAW), Mustang Bio (MBIO), Addex Therapeutics (ADXN), Aptorum Group (APM), Dogwood Therapeutics (DWTX), Biomerica (BMRA), and GENPREX (GNPX). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors NKGen Biotech AEON Biopharma Kiora Pharmaceuticals Traws Pharma Mustang Bio Addex Therapeutics Aptorum Group Dogwood Therapeutics Biomerica GENPREX Entero Therapeutics (NASDAQ:ENTO) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations. Which has more volatility and risk, ENTO or NKGN? Entero Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Is ENTO or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -1,063.82% -26.06% NKGen Biotech N/A N/A -479.36% Does the media prefer ENTO or NKGN? In the previous week, NKGen Biotech had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for NKGen Biotech and 1 mentions for Entero Therapeutics. NKGen Biotech's average media sentiment score of -0.33 beat Entero Therapeutics' score of -1.00 indicating that NKGen Biotech is being referred to more favorably in the news media. Company Overall Sentiment Entero Therapeutics Negative NKGen Biotech Neutral Which has preferable valuation & earnings, ENTO or NKGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$18.06MN/AN/ANKGen BiotechN/AN/A-$82.94M-$2.45-0.06 Do insiders & institutionals hold more shares of ENTO or NKGN? 12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryNKGen Biotech beats Entero Therapeutics on 6 of the 8 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.10M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book-0.518.508.275.54Net Income-$18.06M-$55.06M$3.25B$259.28M7 Day Performance-12.23%-3.99%-3.70%-4.64%1 Month Performance3.80%9.58%4.34%4.41%1 Year Performance-34.49%6.70%25.90%17.95% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$0.42-4.5%N/A-32.2%$2.10MN/A0.009Negative NewsShort Interest ↑NKGNNKGen Biotech0.3549 of 5 stars$0.21-12.5%N/A-86.9%$9.44MN/A-0.04N/AShort Interest ↑Gap DownAEONAEON Biopharma3.3513 of 5 stars$0.83+3.5%$360.00+43,169.2%-99.2%$9.41MN/A4.625KPRXKiora Pharmaceuticals3.1183 of 5 stars$3.06+0.8%$10.00+227.3%-43.9%$9.38M$16.02M-1.0610Upcoming EarningsTRAWTraws PharmaN/A$1.67+3.1%N/AN/A$9.29M$230K-0.0517Positive NewsMBIOMustang Bio0.2 of 5 stars$2.11+0.8%N/A-91.0%$9.24MN/A-0.03100Short Interest ↑ADXNAddex Therapeutics2.8745 of 5 stars$8.66+10.6%$30.00+246.4%+1.3%$9.18M$170.62K-25.4730Positive NewsAPMAptorum Group1.0267 of 5 stars$1.69+4.9%N/A-58.5%$9.09MN/A0.0030DWTXDogwood Therapeutics1.44 of 5 stars$4.75+1.2%$10.00+110.7%N/A$9.06MN/A-0.265Positive NewsUpcoming EarningsGap UpBMRABiomerica0.2073 of 5 stars$3.52-2.2%N/A+31.3%$8.98M$5.41M-1.5260Gap DownGNPXGENPREX1.4699 of 5 stars$0.27-0.7%N/A-86.3%$8.82MN/A0.0020Positive NewsUpcoming EarningsGap Down Related Companies and Tools Related Companies NKGen Biotech Competitors AEON Biopharma Competitors Kiora Pharmaceuticals Competitors Traws Pharma Competitors Mustang Bio Competitors Addex Therapeutics Competitors Aptorum Group Competitors Dogwood Therapeutics Competitors Biomerica Competitors GENPREX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
